Upstream Bio, Inc. (UPB)
NASDAQ: UPB · Real-Time Price · USD
8.78
+0.39 (4.65%)
Apr 28, 2025, 4:00 PM EDT - Market closed
Upstream Bio Revenue
In the year 2024, Upstream Bio had annual revenue of $2.37M, down -0.42%. Upstream Bio had revenue of $613.00K in the quarter ending December 31, 2024, with 36.22% growth.
Revenue (ttm)
$2.37M
Revenue Growth
-0.42%
P/S Ratio
50.69
Revenue / Employee
$45,577
Employees
52
Market Cap
471.39M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.37M | -10.00K | -0.42% |
Dec 31, 2023 | 2.38M | 1.17M | 96.37% |
Dec 31, 2022 | 1.21M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionUPB News
- 11 days ago - Upstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is Imminent - Seeking Alpha
- 4 weeks ago - 3 Dividend Giants To Buy As Tariffs Hit Stocks - Benzinga
- 6 weeks ago - Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - Upstream Bio to Present at Upcoming March Investor Conferences - GlobeNewsWire
- 4 months ago - Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation - Seeking Alpha
- 4 months ago - Upstream Bio Announces Addition to Russell 2000® Index - GlobeNewsWire
- 6 months ago - Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say - Benzinga
- 6 months ago - Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire